TWi Biotechnology, Inc.'s primary business activity is the research and development of new drugs for rare diseases. The selection of indications for new drug development is focused on patient needs, choosing to develop treatments for severe diseases that are currently incurable, emerging, and unmet medical needs. We hope to combine our company's internal clinical, preclinical, animal pharmacology and toxicology research, domestic and foreign pharmaceutical regulations, patent intellectual property protection, international licensing, and rich practical experience in the field of specialty drug development in the United States. Our aim is to develop novel and effective therapeutic drugs to benefit patients, giving them hope for the future. This is the purpose of our company's social responsibility.